Chemotherapy, Radiotherapy and Surgical Tumour Resections in England

2013-2015 diagnoses (July 2018)

The National Cancer Registration and Analysis Service (NCRAS) in partnership with Cancer Research UK (CRUK) has produced population-based statistics on patients recorded to have received chemotherapy, radiotherapy and surgical tumour resections for their tumour in England.

We are now able to routinely report numbers of patients who received treatment, which should help us to identify trends and variation, to hopefully improve outcomes for future patients.

This release (July 2018) updates previous data to include 2015 diagnoses, and shows variation in treatment rates by tumour and patient characteristics, and Cancer Alliance. 

The data focusses on the time period following diagnosis within which most patients' first course of treatment occurred, although adjuvant and neo-adjuvant treatments may be captured as well as the primary treatment. 

Outputs available

Online tool: We have created an easy to navigate tool for viewing and downloading the data.

Workbook 1: “Chemotherapy, Radiotherapy and Tumour Resection by Tumour & Patient Characteristics in England, 2013 – 2015”. This workbook presents the numbers and percentages of tumours diagnosed in England in 2013 - 2015 recorded as receiving radiotherapy, chemotherapy or tumour resection, by cancer site, year, stage at diagnosis, age, sex, deprivation, ethnicity, comorbidities.

Workbook 2: "Chemotherapy, Radiotherapy and Tumour Resection by Cancer Alliance in England, 2013 – 2015”. This workbook presents the numbers and percentages of tumours diagnosed in England in 2013 - 2015 recorded as receiving radiotherapy, chemotherapy or tumour resection, by Cancer Alliance.

The Standard Operating Procedure (SOP) entitled 'CAS-SOP #4.4': The purpose of this SOP is to describe the method of linking treatment tables to the cancer registration data in the Cancer Analysis System (CAS). This allows basic treatment flags to be created; recording whether there was chemotherapy, tumour resection, or radiotherapy recorded following cancer diagnosis. This was the basis of the two workbooks above.

Site-specific summary slides: Graphed results from workbook 1 for each cancer site have been summarised in brief powerpoint decks, with some interpretation added through consultation with site-specific clinicians. These are available below:

Workbook 3 (November 2018): “Chemotherapy, Radiotherapy and Tumour Resection by stage and age, England, 2013 – 2015”. This workbook presents the numbers and percentages of tumours diagnosed in England in 2013 - 2015 recorded as receiving radiotherapy, chemotherapy or tumour resection, by cancer site, followed by the breakdown of age band for each stage at diagnosis. It builds on previous work, and should be used alongside the previous publication "Chemotherapy, Radiotherapy and Tumour Resection by Tumour & Patient Characteristics in England, 2013 - 2015".

2013-2014 diagnoses (corrected February 2018)

The first set of releases, published in October 2017 (corrected in February 2018), included patients diagnosed in 2013-2014, and was split by cancer site and stage at diagnosis. These are available below.

Outputs available

The short report describes the main results of the treatment overview presented in the workbook. This report aims to 1) explain how the data should be interpreted, 2) summarise key results from the accompanying excel workbook, and 3) highlight the methodology used.

The workbook provides an overview of the treatment used in England during 2013 - 2014. This workbook presents the numbers and percentages of tumours diagnosed in England in 2013 - 2014 recorded as receiving radiotherapy, chemotherapy or tumour resection. The results are presented by cancer site, year and stage at diagnosis.

The Standard Operating Procedure (SOP) entitled 'CAS-SOP #4' describes the methodology used.

This work has been used in a number of CRUK outputs, namely health professional pages on Cancer diagnosis and treatment statistics, a science blog and a press release.